Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-26-050431
Filing Date
2026-04-28
Accepted
2026-04-28 16:45:59
Documents
17
Period of Report
2026-06-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A ganx-20260624xdef14a.htm   iXBRL DEF 14A 570343
2 GRAPHIC ganx-20260624xdef14a_a001.jpg GRAPHIC 7845
3 GRAPHIC ganx-20260624xdef14a_bg001.jpg GRAPHIC 187939
4 GRAPHIC ganx-20260624xdef14a_bg002.jpg GRAPHIC 90006
  Complete submission text file 0001104659-26-050431.txt   1724989

Data Files

Seq Description Document Type Size
5 EX-101.SCH ganx-20260624.xsd EX-101.SCH 4020
6 EX-101.DEF ganx-20260624_def.xml EX-101.DEF 3554
7 EX-101.LAB ganx-20260624_lab.xml EX-101.LAB 4689
8 EX-101.PRE ganx-20260624_pre.xml EX-101.PRE 4163
20 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20260624xdef14a_htm.xml XML 94029
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

EIN.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40237 | Film No.: 26908737
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)